David Benditt, MD
Cardiovascular Disease · St Cloud, MNNPI 1073559134
Payments from drug & device makers
Across 79 payments — averaging $178.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$10K
- Abbott$3K
- Boston Scientific$565
- Biotronik Inc.$452
- Biosense Webster, Inc.$194
- Nihon Kohden America, LLC$142
- plus $122 from 3 others
Across 202 payments — averaging $1336.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$270K
What the payments were for
- Speaking & faculty fees$9,69085%
- Travel & lodging$1421%
- Food & beverage$1,59714%
- Education$140%
- Ownership interest$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 6 | $9,745 |
| Abbott | 10 | $2,878 |
| Boston Scientific | 15 | $565 |
| Biotronik Inc. | 40 | $452 |
| Biosense Webster, Inc. | 4 | $194 |
| Nihon Kohden America, LLC | 1 | $142 |
| Impulse Dynamics (USA) Inc. | 1 | $86 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $19 |
| Atricure, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,099 in reported general payments places this provider in the 65th percentile of 451 cardiovascular disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 37 | $56,945 |
| EliquisApixaban | 15 | $21,229 |
| Midodrine Hcl | 94 | $7,558 |
| Fludrocortisone Acetate | 73 | $2,906 |
| Metoprolol Succinate | 53 | $1,278 |
| Sodium Chloride0.9 % Sodium Chloride | 38 | $1,271 |
| Flecainide Acetate | 18 | $781 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 21 | $558 |
| SotalolSotalol Hcl | 11 | $396 |
| Warfarin Sodium | 20 | $194 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in St Cloud
- Jae OhRochester$7.9M
- Yogesh ReddyRochester$7.9M
- Mayra GuerreroRochester$7.1M
- Martha GroganRochester$6.3M
- Leslie ForgoshSaint Paul$6.2M
- Jeffrey ChambersMinneapolis$3.6M
- Mackram EleidRochester$3.5M
- David HolmesRochester$2.4M
- Mohamad Adnan AlkhouliRochester$2.1M
- Srijoy MahapatraRochester$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.